Background. Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia (PCP) is a major cause of mortality in human immunodeficiency virus (HIV)-infected infants in Africa, but the prevalence of mutations in the gene encoding dihydropteroate synthase (DHPS) in isolates from Africa has not been reported.
Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia (PCP) has increasingly been reported as an important cause of hospitalization and death in HIVinfected infants in Africa [1] . Postmortem studies have detected PCP in 16%-51% of HIV-positive African children who died from respiratory illness [2] [3] [4] . In a large, recent, autopsy-based study of Zambian children who died from respiratory causes, P. jiroveci, which was found in 51% of cases, was the most common cause of death in HIV-infected infants !6 months of age; among infants aged 6-11 months, PCP accounted for 19% of deaths [4] . Prospective African studies have confirmed that P. jiroveci is an important cause of severe pneumonia in HIV-infected infants. In a prospective study to investigate the etiology and outcome of com-munity-acquired pneumonia in South African children admitted to a tertiary care hospital, PCP was the AIDSdefining illness in 20% of HIV-infected children; the mortality rate among those with PCP (47%) was much higher than among those without PCP (18%) [5] . Of 93 HIV-infected Malawian children hospitalized with severe pneumonia, 17% had PCP [6] . A South African study of hospitalized HIV-infected children identified P. jiroveci in 44% of the severe pneumonia cases [7] .
Trimethoprim-sulphamethoxazole (TMP-SMZ) is the primary agent of choice for prophylaxis and treatment of PCP. Activity against pneumocystis is primarily due to the sulphamethoxazole component, which inhibits dihydropteroate synthase (DHPS) [8] . Prophylaxis has not been widely used in African countries because of the difficulties in identifying HIV-infected infants perinatally, the lack of resources to implement widespread prophylaxis, and the concern about the development of antimicrobial resistance to TMP-SMZ [9, 10] . Nevertheless, TMP-SMZ is widely available, affordable, and effective for preventing PCP, as has been shown by historical comparisons of the incidence of PCP before the advent of prophylaxis [11] [12] [13] [14] . Use of prophylaxis against PCP has been reported to decrease the risk and severity of this disease in African HIV-infected infants [5] . A study done in Cape Town, South Africa, found that use of TMP-SMZ prophylaxis was associated with significant protection against PCP, because only 1 (1.7%) of 59 children who received prophylaxis developed PCP, compared with 14 (15.2%) of 92 who did not receive prophylaxis (relative risk, 0.11; 95% CI, 0.02-0.82; ) [5] . Use of TMP-SMZ prophylaxis has also been P p .007 reported to be associated with a lower mortality rate among HIV-infected children hospitalized with pneumonia, compared with those who had not received prophylaxis [15] . Current World Health Organization HIV/AIDS guidelines recommend the use of TMP-SMZ prophylaxis in all HIV-exposed infants who are between 6 weeks and 15 months of age and in clinically symptomatic HIV-infected children and adults or those with severe immunosuppression (i.e., those with a CD4 cell percentage of !15%) [16] . More-widespread use of TMP-SMZ prophylaxis can be anticipated as these guidelines are implemented in African countries.
Mutations in the P. jiroveci gene coding for DHPS have been increasingly reported in isolates in developed countries, in association with widespread use of TMP-SMZ prophylaxis [17] [18] [19] [20] . The most common DHPS mutations reported are an amino acid change at positions 55 (from threonine to alanine) and 57 (from proline to serine). Studies have found that mutant strains are associated with the failure of TMP-SMZ prophylaxis [17] [18] [19] [20] . An increased mortality rate associated with the presence of DHPS mutations in cases of PCP has been reported. However, no correlation between specific treatment, DHPS mutations, and outcome was described [21] . The prevalence of mutant P. jiroveci isolates in Africa has not been reported. Because the use of TMP-SMZ prophylaxis is increasing in African countries and the majority of HIV-infected people in Africa reside in the sub-Saharan region, it is becoming increasingly important to monitor the development and prevalence of mutant strains in this geographical area. The aim of this study was to investigate the prevalence of DHPS mutations in P. jiroveci isolates from HIV-infected children hospitalized with PCP in Cape Town.
METHODS
A prospective study of P. jiroveci isolates obtained from HIVinfected children admitted for PCP over a 2-year period to Red Cross Childrens Hospital, University of Cape Town, South Africa, was performed. Children admitted to the hospital with clinical signs suggestive of PCP had respiratory specimens obtained for diagnosis. Treatment with a standard regimen of TMP-SMZ (10 mg/kg TMP loading dose, followed by 5 mg/ kg q6h) and corticosteroids (2 mg/kg prednisone for 5 days, then 1 mg/kg for 5 days, followed by 0.5 mg/kg for 5 days) was initiated. Specimens of induced sputum or nondirected bronchoalveolar lavage (BAL) fluid were obtained for immunofluorescent detection of P. jiroveci, as described elsewhere [22] . Samples with positive immunofluorescence results were pelleted, placed in ethanol, and delivered to the University of North Carolina-Chapel Hill for further analysis. The study was approved by the research and ethics committees of the University of Cape Town and the University of North CarolinaChapel Hill.
The QIAamp DNA extraction kit (Qiagen) was used to extract DNA from the pellet obtained after centrifugation of sputum or BAL specimens. DNA was amplified by PCR in a programmable thermal controller (MJ Research) using a nested PCR protocol, as described elsewhere [20, 23, 24] . Two different polymerases-the classical recombinant Taq DNA polymerase (Invitrogen) and the new-generation HotStar Taq polymerase (Qiagen)-were used. The same set of primers, each with different programs in the thermocycler, were used with both polymerases. In the first round of PCR, the primers F 1 (5 -CCTGGT-ATTAAACCAGTTTTGCC-3 ) and B 45 (5 -CAATTTAATAAA-TTTCTTTCCAAATAGCATC-3 ) were used. In the second round, the primers were A HUM (5 -GCGCCTACACATATTATGGCCA-TTTTAAATC-3 ) and BN (5 -GGAACTTTCAACTTGGCAAC-CAC-3 ). The PCR mixtures contained template DNA (5 mL), primers (0.4 mmol/L each), dNTPs (0.2 mmol/L), and MgCl 2 (2 mmol/L) if Taq DNA polymerase (2.5 U) was used, but no MgCl 2 if HotStar Taq polymerase (2.5 U) was used, as well as reaction buffer (each polymerase had its own buffer) and water, making a total volume of 100 mL.
When recombinant Taq DNA polymerase was used, thermocycler settings for the first round were denaturation at 94ЊC for 5 min, followed by 35 cycles at 92ЊC for 30 s, 52ЊC for 30 s, and 72ЊC for 60 s, and a termination step at 72ЊC for 5 min. Thermocycler settings for the second round were 94ЊC for 5 min, followed by 35 cycles of 92ЊC for 30 s, 55ЊC for 30 s, and 72ЊC for 60 s, and a termination step at 72ЊC for 5 min. The same conditions were employed when HotStar Taq polymerase was used, except that the initial denaturation step (for both the first and second rounds) was 95ЊC for 15 min instead of 94ЊC for 5 min.
For positive controls, BAL specimens obtained from HIVinfected patients with PCP and known DHPS sequences were were used, whereas BAL specimens obtained from HIV-infected patients without PCP were used as negative controls. For analysis of the PCR-generated fragments, 8 mL of each 100-mL PCR amplification product was examined by electrophoresis on 2% agarose gels for a band of 335 bp corresponding to the size of the P. jiroveci gene encoding DHPS. The DNA from the agarose gel band was purified with the QIAquick gel extraction kit (Qiagen), according to the manufacturer's directions. The PCR fragments were sequenced on an automated DNA sequencer (model ABI 3700; Applied Biosystems), using 2 of the primers described above. Sequence analyses were performed using Chromas 2.23 (Technelysium Pty. Ltd.), ClustalX 1.8, and GeneDoc (multiple sequence alignment editor, version 2.6.002), and the results were compared with the wild-type sequence for the P. jiroveci gene encoding DHPS. Results were analyzed using Epi Info, version 6.4 (Centers for Disease Control and Prevention). Mortality among children infected with wild-type P. jiroveci was compared with that among children infected with mutant strains using the x 2 test.
RESULTS
Results of immunofluorescence for PCP were positive for 33 respiratory specimens obtained from 33 HIV-infected children. Of these, 30 samples were amplified using 1 of the 2 sets of PCR protocols. Of the 30 children, 20 (66.7%) were male; the mean age was 3.2 months (range, 1.5-12 months). Only 1 child was taking TMP-SMZ prophylaxis, because HIV infection had not been previously diagnosed in the others. In 29 children (97%), PCP was the presenting illness that resulted in a diagnosis of HIV infection. A total of 28 children (93.3%) were admitted to an intensive care unit. A total of 26 samples (86.7%) were infected with P. jiroveci with wild-type DHPS alleles, whereas 4 specimens (13.3%) contained DHPS mutations (table 1). Three of these 4 specimens contained homogenous P. jiroveci isolates-the first contained a double mutation in DHPS consisting of a change at amino acid 55 and a change at amino acid 57, the second had a single polymorphism at amino acid 57, and the third contained a change at amino acid 55. One sample contained a heteroge-neous population of P. jiroveci isolates consisting of a wild-type strain and a strain with a single mutation at amino acid 55.
Twenty children (66.7%) died during hospitalization, including the single child receiving TMP-SMZ prophylaxis. The mortality rate among children infected with wild-type P. jiroveci (17 [65.4%] of 26 children) was not significantly different, compared with those infected with mutant strains (3 [75%] of 4 children) ( ). P p .8
DISCUSSION
This study is the first to report on the prevalence of P. jiroveci DHPS mutations in Africa. Most cases of PCP in South African children were caused by wild-type P. jiroveci, but DHPS mutations at codons 55 and 57, which may be responsible for lowlevel resistance to drugs containing sulphur, occurred in a minority of isolates. This is in contrast to reports from the United States, where the prevalence of DHPS mutations reported in patients with AIDS and PCP has been reported to be 43%-68% [17] [18] [19] [20] . The low prevalence of mutant P. jiroveci observed in our study may be due to the lack of exposure to TMP-SMZ prophylaxis in almost all of the children. In addition, TMP-SMZ is rarely used for treatment of childhood illnesses (other than PCP) in South Africa because of high levels of antimicrobial resistance to this drug. Thus, a b-lactam antibiotic or a cephalosporin, rather than TMP-SMZ, would be the preferred drug for therapy of childhood pneumonia, otitis media, or other common bacterial infections and, consequently, the majority of children would not be exposed to sulphur-containing drugs [25] . Studies from the United States indicate that development of DHPS mutations occurs more commonly in HIVinfected patients with PCP who have received sulphur prophylaxis, is related to duration of prophylaxis, and has increased over time in association with greater use of TMP-SMZ prophylaxis [17] [18] [19] [20] . The occurrence of mutations in children who had not received prior TMP-SMZ prophylaxis may possibly be ascribed to primary infection acquired from a person infected with a mutant strain. In support of this, a recent report described probable mother-to-child transmission of pneumocystis infection [26] . In addition, mutant strains have increasingly been found in HIV-infected people in the United States who have not been receiving prophylaxis [19] . However, we were unable to test this hypothesis, because we could not obtain clinical information or samples from the mothers or close contacts of children in our study.
The high mortality observed in this study, which occurred despite the use of intensive care unit facilities and antipneumocystis therapy including steroids, is consistent with the poor outcome reported for HIV-infected children with PCP in developing countries [5] [6] [7] . Mortality could not be ascribed to resistance to TMP-SMZ among children in our study, because mortality rates were similar among those who were infected with wild or mutant strains. Moreover, the clinical significance of DHPS mutations at positions 55 and 57 is unclear. Failure to prevent PCP in patients receiving TMP-SMZ prophylaxis and infection with mutant P. jiroveci suggests that such mutations may confer a low level of resistance that is sufficient to overcome the inhibitory effect of prophylaxis. However, the effect of mutant strains on clinical illness and outcome from PCP is controversial, and the efficacy of high-dose TMP-SMZ therapy may be variable. A few studies have reported a similar outcome among HIV-infected patients with wild-type and mutant PCP, whereas others have found that patients infected with mutant strains have a poorer response to therapy [18, 21, 27] . In addition, in our study, a type 2 error may have occurred because of the small sample size. Larger studies of the relationship between clinical outcome and infection with mutant strains in developing countries are needed.
Use of TMP-SMZ prophylaxis can substantially reduce the incidence of PCP [5, [11] [12] [13] [14] , especially in resource-poor countries where relatively few HIV-infected people have access to HAART. In addition, adult data from West Africa suggests that TMP-SMZ prophylaxis can significantly reduce morbidity and mortality from other bacterial infections [28] [29] [30] . The high mortality associated with primary pneumocystis infection in children and the emergence of PCP as an increasingly important infection in African patients [1] indicate that timely identification of HIV-infected infants and use of TMP-SMZ prophylaxis should be a priority [9] . However, as TMP-SMZ prophylaxis is increasingly used, so the potential for emergence of DHPS mutations may occur, as is evident in developed countries. Moreover, studies from developed countries suggest that person-to-person transmission of pneumocystis may occur. Thus, as the prevalence of mutant strains increases, the potential for primary infection with resistant strains in children not receiving prophylaxis may increase [19, 25] . Ongoing monitoring of the development of mutant P. jiroveci strains in African countries is therefore becoming increasingly important and may help to elucidate the mechanisms responsible for the development of resistance and the associated clinical implications.
DHPS mutations are uncommon in P. jiroveci isolates from HIV-infected children in Cape Town. DHPS mutations at codons 55 and 57, which may be responsible for low-level resistance to therapy that includes sulphur, are only beginning to accumulate. However, increasing use of TMP-SMZ prophylaxis may result in more-widespread development of mutations; ongoing surveillance of this is needed.
